Charles B. Glaser is a notable inventor based in San Francisco, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of thrombomodulin analogs. With a total of 2 patents, his work focuses on enhancing therapeutic options for thrombotic conditions.

Latest Patents

Glaser's latest patents include "Superior thrombomodulin analogs for pharmaceutical use" and "Oxidation resistant thrombomodulin analogs." The first patent relates to analogs of thrombomodulin that enhance the thrombin-mediated activation of protein C while reducing the procoagulant activities of thrombin. These analogs are particularly useful in antithrombotic therapy, providing novel proteins, nucleic acid gene sequences, and methods for inhibiting thrombotic activity. The second patent describes soluble oxidation-resistant thrombomodulin analogs that maintain therapeutic properties even after exposure to oxidants. These multifunctional fusion proteins exhibit both antithrombotic activity and additional bioactivity, making them valuable in treating thrombotic and vascular diseases.

Career Highlights

Glaser's career is marked by his innovative approach to pharmaceutical development. His work at Schering Aktiengesellschaft has positioned him as a key figure in the advancement of thrombomodulin therapies. His contributions have the potential to significantly impact patient care in thrombotic conditions.

Collaborations

Throughout his career, Glaser has collaborated with notable professionals in the field, including Michael John Morser and David Richard Light. These collaborations have further enriched his research and development efforts.

Conclusion

Charles B. Glaser's innovative work in thrombomodulin analogs showcases his commitment to advancing pharmaceutical therapies. His patents reflect a deep understanding of the complexities of thrombotic conditions and offer promising solutions for improved patient outcomes.